Aquestive Therapeutics, Inc.
AQSTHealthcareNASDAQDrug Manufacturers - Specialty & Generic
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Aquestive Therapeutics, Inc. focuses on Drug Manufacturers - Specialty & Generic services and products. Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. At a $502.0M market cap, Aquestive Therapeutics, Inc. ranks as a small-cap company within healthcare. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; EMYLIF, an oral film formulation of riluzole; ONDIF, an oral soluble film formulation of ondansetron; SYMPAZAN, an oral soluble film formulation of clobazam used for the treatment of seizures associated with a rare, intractable form of epilepsy; KYNMOBI, a sublingual film formulation of apomorphine; and AZSTARYS, an fda-approved, once-daily product for the treatment of ADHD in patients age 6 years or older.
Market Cap
$502.0M
Beta
1.49
P/E (TTM)
—
P/E (Fwd)
-7.02
EPS (TTM)
$-0.64
EPS (Fwd)
$-0.57
ROE
—
ROA
-29.2%
Cash
$98.5M
Total Debt
$59.0M
Free CF
-$26.9M
52W Change
-41.5%
Annual Financials
Cash vs Debt
Where AQST stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, AQST finished 11.34% below its 150-day moving average ($4.32) and 9.88% below its 200-day moving average ($4.25). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is AQST overbought or oversold?
At the October 20, 2026 close, AQST's RSI(14) was 25.0, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $98.5M in cash and $59.0M in debt, AQST maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$26.9M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Revenue has been relatively flat, moving from $47.7M (2022) to $44.5M (2025).
Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Aquestive Therapeutics, Inc. and its sector.